Form 4: NeuroPace CMO Martha Morrell Reports Stock Transaction

Chief Medical Officer Martha Morrell disposed of 358 shares of NeuroPace common stock to satisfy tax withholding obligations.

Summary

• Chief Medical Officer Martha Morrell sold 358 shares of NeuroPace Inc. (NPCE) common stock.
• The transaction occurred on May 27, 2026, at a price of $17.06 per share.
• The disposal was executed to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following this transaction, the reporting person maintains a beneficial ownership of 52,385 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a mandatory tax-related transaction rather than a strategic shift or market-driven divestment.

Positives

• The transaction was a routine administrative action related to tax obligations rather than a discretionary market sale.

Negatives

• Reduction in the total number of shares held by a key executive.

Risks

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive equity management, common in the medical device sector, and does not signal a change in corporate strategy or executive sentiment.

Comparison to Industry Standards

• The transaction aligns with standard industry practices for managing tax obligations arising from equity-based compensation plans.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was non-discretionary and related to tax compliance.

Key Dates

Keywords

NeuroPace, NPCE, Form 4, Insider Trading, Martha Morrell, Tax Withholding, Executive Compensation